Marea Therapeutics Initiated Phase 2 Acromegaly Trial

The biotech firm has dosed the first patient in a mid-stage study evaluating its monoclonal antibody treatment.

Updated on Oct. 5, 2026 in Biotech

Marea Therapeutics Initiated Phase 2 Acromegaly Trial

Live Poll

Do you believe new pharmaceutical therapies are successfully reducing the burden of managing chronic health conditions?

Marea Therapeutics has begun a Phase 2 clinical trial for its drug candidate MAR002, which is designed to treat the chronic disorder acromegaly. The study aims to test if the monoclonal antibody can effectively block growth hormone signaling.

Why it matters

Acromegaly is a condition caused by excessive growth hormone exposure, and new therapies are sought to reduce the burden of daily injections. Marea Therapeutics hopes its treatment will allow for dosing as infrequently as once every two weeks.

The clinical trial utilizes an initial 900 mg loading dose of the allosteric monoclonal antibody MAR002, with participants assessed for IGF-1 reduction after 10 weeks. This therapy targets the growth hormone receptor to block signaling at the cellular level.

The players

Marea Therapeutics

A South San Francisco-based biotech firm and subsidiary of Lisata Therapeutics that focuses on developing treatments for endocrine disorders.

Lisata Therapeutics

A biopharmaceutical company headquartered in Liberty Corner, New Jersey, that specializes in identifying and developing innovative therapies.

The details

The study design incorporates three distinct dose arms to compare against a placebo group for approximately 72 participants. Patients who complete the primary endpoint assessment may be eligible to transition into an open-label extension trial.

June 2026: Phase 1 trial results were presented.
October 5, 2026: The first patient was dosed in the Phase 2 clinical trial.

The Tech Race

This development represents a move toward long-acting biologics that aim to displace daily injection regimens for chronic hormone conditions. By targeting the growth hormone receptor, the company is competing to establish a best-in-class profile within the endocrine biotech space.

For patients, the successful development of this drug could eventually eliminate the need for daily medication by enabling bi-weekly dosing schedules. This change would significantly improve the daily quality of life and treatment adherence for those living with acromegaly.

The takeaway

Advancements in monoclonal antibody treatments continue to shift the standard for managing chronic conditions that require long-term care. Patients dealing with long-term disorders should monitor clinical trial progress, as these studies often define the future availability of new options.